

Supplementary Table S1. Additional baseline patient demographics and clinical characteristics									
	Study population								
	ITT	RAS mutation				BRAF mutation			
	Total (n=566)	Total (n=210)	Arm A (n=63)	Arm B (n=72)	Arm C (n=75)	Total (n=55)	Arm A (n=19)	Arm B (n=20)	Arm C (n=16)
<b>Age (years)</b>									
Median (range)	62 (24-75)	62 (27-75)	61 (41-75)	62 (27-74)	63 (33-74)	61 (34-74)	63 (35-72)	59 (34-73)	62 (44-74)
<b>Gender, n (%)</b>									
Male	334 (59)	121 (58)	42 (67)	38 (53)	41 (55)	26 (47)	8 (42)	9 (45)	9 (56)
Female	232 (41)	89 (42)	21 (33)	34 (47)	34 (45)	29 (53)	11 (58)	11 (55)	7 (44)
<b>WHO Performance status, n (%)</b>									
0	380 (67)	143 (68)	42 (67)	51 (71)	50 (67)	35 (64)	12 (63)	13 (65)	10 (63)
1	162 (29)	59 (28)	20 (32)	19 (26)	20 (27)	17 (31)	7 (37)	6 (30)	4 (25)
2	24 (4)	8 (4)	1 (2)	2 (3)	5 (7)	3 (6)	0	1 (5)	2 (13)
<b>Site of primary tumour, n (%)</b>									
Colon	333 (59)	115 (55)	29 (46)	41 (57)	45 (60)	49 (89)	18 (95)	17 (85)	14 (88)
Rectum	233 (41)	95 (45)	34 (54)	31 (43)	30 (40)	6 (11)	1 (5)	3 (15)	2 (13)
<b>Previous treatment, n (%)</b>									
Primary tumour resected	382 (68)	157 (75)	50 (79)	52 (72)	55 (73)	44 (80)	13 (68)	17 (85)	14 (88)
Adjuvant chemotherapy	51 (9)	15 (7)	5 (8)	2 (3)	8 (11)	10 (18)	3 (16)	5 (25)	2 (13)
Preoperative radiotherapy	80 (14)	35 (17)	11 (18)	9 (13)	15 (20)	6 (11)	1 (5)	3 (15)	2 (13)
<b>Timing of metastases, n (%)</b>									
Synchronous	402 (71)	141 (67)	40 (64)	47 (65)	54 (72)	38 (69)	14 (74)	14 (70)	10 (63)
Metachronous	164 (29)	69 (33)	23 (37)	25 (35)	21 (28)	17 (31)	5 (26)	6 (30)	6 (38)
<b>Number of metastatic sites, n (%)</b>									
1 site	162 (29)	60 (29)	17 (27)	25 (35)	18 (24)	9 (16)	3 (16)	5 (25)	1 (6)
>1 sites	404 (71)	150 (71)	46 (73)	47 (65)	57 (76)	46 (84)	16 (84)	15 (75)	15 (94)
<b>Type of metastases, n (%)</b>									
Liver only	107 (19)	34 (16)	11 (18)	15 (21)	8 (11)	3 (6)	1 (5)	2 (10)	0
Liver plus other	312 (55)	120 (57)	34 (54)	36 (50)	50 (67)	31 (56)	10 (53)	9 (45)	12 (75)
Non-liver	147 (26)	56 (27)	18 (29)	21 (29)	17 (23)	21 (38)	8 (42)	9 (45)	4 (25)
<b>Investigations, n (%)</b>									
Alkaline phosphatase level normal	298 (53)	124 (59)	39 (62)	40 (56)	45 (60)	26 (47)	9 (47)	8 (40)	9 (56)
Platelet count < 400 per nL	398 (70)	152 (72)	42 (67)	54 (75)	56 (75)	34 (62)	13 (68)	10 (50)	11 (69)
White blood cell count < 10 per nL	428 (76)	166 (79)	52 (83)	56 (78)	58 (77)	41 (75)	15 (79)	14 (70)	12 (75)
Abbreviations: ITT, Intention-to-treat									